COPD: Combo Tx Promising for Rapid Bronchodilation
(MedPage Today) -- Greater than 100 ml increase in peak FEV1 with RPL554 plus Spiriva (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 22, 2018 Category: Primary Care Source Type: news
Expanded asthma indication for SPIRIVA RESPIMAT in EU
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 16, 2018 Category: Research Source Type: news
Safety of Tiotropium in Children with Persistent Asthma
Results of the first study to evaluate use of the adult COPD drug in children age 5 years and younger lay fertile ground for future trials. (Source: ConsultantLive)
Source: ConsultantLive - February 20, 2018 Category: Internal Medicine Authors: Veronica Hackethal, MD Tags: Asthma Source Type: news
Tiotropium cost effective alternative to omalizumab
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news
COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma
A new study provides preliminary evidence that tiotropium, a long-acting anticholinergic drug used for chronic obstructive pulmonary disease (COPD), is safe and effective in preschool-age children with asthma symptoms not well controlled by inhaled corticosteroids.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 26, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Tiotropium to Slow Lung Function Decline in Early COPD Tiotropium to Slow Lung Function Decline in Early COPD
Dr Andy Shorr comments on the thought-provoking findings of the TIO COPD study.Medscape Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Commentary Source Type: news
SPIRIVA ® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New Analyses: Adding SPIRIVA ® Respimat® Effective for Uncontrolled Asthma
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat ® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS† treatment
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
" AAAAI 2014 ASTHMA: New Phase III data show tiotropium* Respimat ® effective across asthma severities "
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Landmark TIOSPIRTM trial reinforces importance of SPIRIVA ® in both available formulations as the world's leading maintenance therapy for chronic obstructive pulmonary disease (COPD)
Landmark TIOSPIRTM trial reinforces importance of SPIRIVA ® in both available formulations as the world ' s leading maintenance therapy for chronic obstructive pulmonary disease (COPD) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Phase III results: tiotropium* Respimat ® is effective in symptomatic asthma patients irrespective of their allergic status
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Tiotropium Respimat ® improved lung function in children with asthma
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Additional results from post-hoc analysis underline effectiveness of SPIRIVA ®
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New large-scale study to investigate effect of tiotropium + olodaterol Respimat ® on exacerbations in COPD
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
